Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Downgraded to Hold Rating by Zacks Research

Key Points

• Bayer Aktiengesellschaft has been downgraded by Zacks Research from a "strong-buy" rating to a "hold" rating, indicating a shift in analyst sentiment.
• Despite the downgrade, other research firms have recently upgraded Bayer, with HSBC Global Research and Kepler Capital Markets raising their ratings to "strong-buy" and "buy," respectively.
• Bayer reported earnings of $0.35 per share for the last quarter, surpassing analysts' expectations of $0.25 and indicating stronger-than-expected revenue of $12.42 billion.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research note issued on Monday,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, June 11th. Wall Street Zen upgraded shares of Bayer Aktiengesellschaft from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Finally, Kepler Capital Markets upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Wednesday, June 11th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Bayer Aktiengesellschaft has a consensus rating of "Buy".

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY traded down $0.09 during trading hours on Monday, reaching $8.24. 659,540 shares of the stock traded hands, compared to its average volume of 630,126. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $8.65. The company's 50-day moving average price is $7.99 and its two-hundred day moving average price is $7.08. The company has a market cap of $32.38 billion, a P/E ratio of -8.49 and a beta of 0.93.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.35 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.10. The company had revenue of $12.42 billion for the quarter, compared to analysts' expectations of $10.79 billion. Bayer Aktiengesellschaft had a negative net margin of 7.61% and a positive return on equity of 15.44%. On average, analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.